X. Fang

发表

Massively Parallel Signature Sequencing and Bioinformatics Analysis Identifies Up-Regulation of TGFBI and SOX4 in Human Glioblastoma

L. Hood, A. Madan, D. Hwang, 2010, PloS one.

Genome-wide analysis of OCT4 binding sites in glioblastoma cancer cells

Na Zhao, Biao-yang Lin, X. Fang, 2011, Journal of Zhejiang University SCIENCE B.

Left-sided primary tumor is a favorable prognostic factor for metastatic colorectal cancer patients receiving surgery

X. Fang, Ying Yuan, K. Ding, 2017, Oncotarget.

Different treatment strategies and molecular features between right-sided and left-sided colon cancers.

X. Fang, Ying Yuan, Hong Shen, 2015, World journal of gastroenterology.

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib

X. Fang, Shenglin Ma, Ying Yuan, 2012, World Journal of Surgical Oncology.

Metastatic mixed acinar‐neuroendocrine carcinoma of the pancreas treated by a multidisciplinary team: A case report and brief review of the literature

X. Bai, X. Fang, Q. Wei, 2019, Journal of digestive diseases.

Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma

Xia Li, X. Fang, Ying Yuan, 2018, OncoTargets and therapy.

SOX4 inhibits GBM cell growth and induces G0/G1 cell cycle arrest through Akt-p53 axis

R. Mao, Yingying Ma, Na Zhao, 2014, BMC Neurology.

Acute small bowel obstruction: a rare initial presentation for the metastasis of the large-cell carcinoma of the lung

X. Fang, Ying Yuan, K. Ding, 2012, World Journal of Surgical Oncology.

A Novel and Reliable Method to Detect Microsatellite Instability in Colorectal Cancer by Next-Generation Sequencing.

Jinghong Xu, X. Fang, Jinghong Xu, 2017, The Journal of molecular diagnostics : JMD.

Hyperprogressive disease in patients receiving immune checkpoint inhibitors.

X. Fang, Linzhen Yu, Mengyuan Yang, 2020, Current problems in cancer.

Diverse fragment lengths dismiss size selection for serum cell-free DNA: a comparative study of serum and plasma samples

X. Fang, Yanqin Huang, Ying Yuan, 2020, Clinical chemistry and laboratory medicine.

REV1: A novel biomarker and potential therapeutic target for various cancers

X. Fang, Shanshan Weng, N. Zhu, 2022, Frontiers in Genetics.

Integrated Expression Profiling and ChIP-seq Analyses of the Growth Inhibition Response Program of the Androgen Receptor

Daehee Hwang, Gilbert S. Omenn, Xuefeng Fang, 2009, PloS one.

Expression of Lysine-specific demethylase 1 in human epithelial ovarian cancer

X. Fang, Chunqing Yang, Qibin Lu, 2015, Journal of Ovarian Research.

Landscape of the SOX2 protein–protein interactome

L. Hood, D. Goodlett, Jae-Geun Yoon, 2011, Proteomics.

Silencing SOX2 Induced Mesenchymal-Epithelial Transition and Its Expression Predicts Liver and Lymph Node Metastasis of CRC Patients

L. Hood, X. Fang, G. Foltz, 2012, PloS one.

The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray, and microRNA analysis

Wei Yu, David R Goodlett, Xuefeng Fang, 2011, BMC Genomics.

A quantitative quality control method of big data in cancer patients using artificial neural network

Licheng Yu, Hong Shen, Tianzhou Chen, 2014, 2014 IEEE 3rd International Conference on Cloud Computing and Intelligence Systems.

ChIP-seq and functional analysis of the SOX2 gene in colorectal cancers.

Sheng-Cai Lin, X. Fang, Z. Ye, 2010, Omics : a journal of integrative biology.

Special AT-rich sequence-binding protein 1 promotes cell growth and metastasis in colorectal cancer.

X. Fang, Xiao-Feng Li, Ying Yuan, 2013, World journal of gastroenterology.

Clinical significance of Ankyrin repeat domain 12 expression in colorectal cancer

Shu Zheng, X. Fang, Dan Li, 2013, Journal of experimental & clinical cancer research : CR.

A new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer

X. Fang, Ying Yuan, Xiaofen Li, 2016, OncoTargets and therapy.

Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors

X. Fang, Shanshan Weng, Linzhen Yu, 2019, Journal of Cancer Research and Clinical Oncology.

Report of two cases and a systematic review of breast cancer with gastrointestinal metastasis.

X. Fang, Jinlong Tang, Ying Yuan, 2019, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

Successful treatment of metastatic colorectal cancer with synchronous BRAF V600E mutation and dMMR with BGB-A317.

X. Fang, Yi Cheng, Ying Yuan, 2020, Immunotherapy.

The efficacy of low‐power cumulative high‐intensity focused ultrasound treatment for recurrent desmoid tumor

X. Fang, Yuebing Wang, Xiaoye Hu, 2022, Cancer medicine.

Efficacy of vemurafenib in a heavy smoker with BRAF-mutated lung adenocarcinoma: A case report and literature review.

X. Fang, Ying Yuan, Ying Chen, 2018, Molecular and clinical oncology.

Long Noncoding RNAs Expression Patterns Associated with Chemo Response to Cisplatin Based Chemotherapy in Lung Squamous Cell Carcinoma Patients

Zhibo Hou, Xuefeng Fang, Ping Zhan, 2014, PloS one.

Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing

X. Fang, Shanshan Weng, Mengyuan Yang, 2018, Cancer biology & therapy.

Evaluation of therapeutic effect of tumor-targeted therapy

X. Fang, Pintong Huang, Ying Yuan, 2012, OncoTargets and therapy.

Identification of Kininogen 1 as a Serum Protein Marker of Colorectal Adenoma in Patients with a Family History of Colorectal Cancer

X. Fang, Jiekai Yu, Yanqin Huang, 2018, Journal of Cancer.

Influence of high intensity focused ultrasound (HIFU) treatment to the pancreatic function in pancreatic cancer patients.

X. Fang, J. Zhao, Xiaoye Hu, 2015, Pakistan journal of pharmaceutical sciences.

Prognostic Role of BRAF Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials

X. Fang, Ying Yuan, Dan Li, 2016, PloS one.

Identification and prognostic analysis of the cetuximab resistance-related gene REV1 in RAS wild-type metastatic colorectal cancer.

X. Fang, Shanshan Weng, N. Zhu, 2021, American journal of cancer research.

ChIP-seq and functional analysis of the SOX2 gene in colorectal cancers.

Sheng-Cai Lin, X. Fang, Z. Ye, 2010, Omics : a journal of integrative biology.

Development and validation of a novel prognostic nomogram including tumor deposits could better predict survival for colorectal cancer: a population-based study

X. Fang, Linzhen Yu, Mengyuan Yang, 2021, Annals of translational medicine.

Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study

X. Fang, Jian Wang, Shanshan Weng, 2023, BMC Cancer.

Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial

X. Fang, Jian Wang, Hongfeng Cao, 2023, EClinicalMedicine.

Identification of the biomarkers for the prediction of efficacy in first-line chemotherapy of metastatic colorectal cancer patients using SELDI-TOF-MS and artificial neural networks.

X. Fang, Jiekai Yu, Ying Yuan, 2012, Hepato-Gastroenterology.

Camrelizumab, chemotherapy and apatinib in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trial

X. Fang, Zixiang Wu, Qi Wang, 2024, EClinicalMedicine.